M Caccese, I Desideri, V Villani, M Simonelli, M Buglione, S Chiesa, E Franceschi, P Gaviani, I Stasi, C Caserta, S Brugnara, I Lolli, E Bennicelli, P Bini, A S Cuccu, S Scoccianti, M Padovan, S Gori, A Bonetti, P Giordano, A Pellerino, F Gregucci, N Riva, S Cinieri, V Internò, M Santoni, G Pernice, C Dealis, L Stievano, F Paiar, G Magni, G L De Salvo, V Zagonel, G Lombardi
BACKGROUND: In the randomized phase II REGOMA trial, regorafenib showed promising activity in patients with recurrent glioblastoma. We conducted a large, multicenter, prospective, observational study to confirm the REGOMA data in a real-world setting. PATIENTS AND METHODS: The major inclusion criteria were histologically confirmed diagnosis of glioblastoma according to the World Health Organization (WHO) 2016 classification and relapse after radiotherapy with concurrent/adjuvant temozolomide treatment, good performance status [Eastern Cooperative Oncology Group performance status (ECOG PS 0-1)] and good liver function...
March 15, 2024: ESMO Open